https://www.selleckchem.com/pr....oducts/Staurosporine
Extension of adjuvant endocrine therapy (ET) reduces the risk of recurrence in women diagnosed with ER-positive breast cancers, but a significant benefit is unlikely to happen to all individual patients. This study is aimed at evaluating the ability of different clinical late distant recurrence (LDR) risk stratification methods and in particular the clinical treatment score at 5years (CTS5) to predict the response to extended adjuvant ET. 783 patients diagnosed with ER+ BC between 1988 and 2014 at Umberto I Hospital of Turin, of w